Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Sep 1;142(9):e47.
doi: 10.1093/brain/awz224.

LATE to the PART-y

Affiliations
Free PMC article
Comment

LATE to the PART-y

Keith A Josephs et al. Brain. .
Free PMC article

Erratum in

  • Corrigendum.
    Brain. 2019 Dec 1;142(12):e73. doi: 10.1093/brain/awz263. Brain. 2019. PMID: 31504223 Free PMC article. No abstract available.

Figures

Figure 1
Figure 1
TDP-43 immunoreactive inclusions can be found in many different neurodegenerative diseases. Currently TDP-43 proteinopathies are divided into primary TDP-43 proteinopathies and mixed (secondary) TDP-43 proteinopathies. AD = Alzheimer’s disease; ALS = amyotrophic lateral sclerosis; CBD = corticobasal degeneration; CTE = chronic traumatic encephalopathy; FTLD = frontotemporal lobar degeneration; LBD = Lewy body disease; PART = primary age related tauopathy; PDC = Parkinson-dementia complex; PSP = progressive supranuclear palsy; SCA = spinocerebellar ataxia.

Comment in

  • Reply: LATE to the PART-y.
    Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, Coyle-Gilchrist ITS, Fardo DW, Flanagan ME, Halliday G, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GG, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murray ME, Nag S, Seeley WW, Sperling RA, White CL, Schneider JA. Nelson PT, et al. Brain. 2019 Sep 1;142(9):e48. doi: 10.1093/brain/awz226. Brain. 2019. PMID: 31359039 No abstract available.

Comment on

  • Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report.
    Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, Coyle-Gilchrist ITS, Chui HC, Fardo DW, Flanagan ME, Halliday G, Hokkanen SRK, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GG, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murayama S, Murray ME, Nag S, Rissman RA, Seeley WW, Sperling RA, White Iii CL, Yu L, Schneider JA. Nelson PT, et al. Brain. 2019 Jun 1;142(6):1503-1527. doi: 10.1093/brain/awz099. Brain. 2019. PMID: 31039256 Free PMC article.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 2007; 61: 435–45. - PMC - PubMed
    1. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006; 351: 602–11. - PubMed
    1. Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K et al. Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol 2009; 117: 125–36. - PubMed
    1. Arnold SJ, Dugger BN, Beach TG. TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol 2013; 126: 51–7. - PMC - PubMed
    1. Berkwits M. Capture! Shock! Excite! Clinical trial acronyms and the “branding” of clinical research. Ann Intern Med 2000; 133: 755–62. - PubMed

Substances

Feedback